Description

tert-Butyl 3-Hydroxy-6,6-Dimethyl-6,7-Dihydro-1H-Pyrazolo[4,3-B]Pyridine-4(5H)-Carboxylate is a high-value, advanced pharmaceutical intermediate characterized by its fused pyrazolopyridine heterocyclic structure. This compound is critical for the synthesis of novel active pharmaceutical ingredients (APIs), particularly in therapeutic areas requiring complex molecular scaffolds. It is primarily sought after by research organizations, contract development and manufacturing organizations (CDMOs), and pharmaceutical companies engaged in the development of new chemical entities.

Application

• Pharmaceutical Intermediate: Key building block in the synthesis of novel drug candidates targeting central nervous system (CNS) disorders, oncology, and inflammatory diseases.
• Medicinal Chemistry Research: Used in lead optimization and structure-activity relationship (SAR) studies to develop compounds with improved potency and selectivity.
• Process Chemistry Development: Serves as a critical intermediate for scaling up synthetic routes under current Good Manufacturing Practice (cGMP) conditions.
• Biochemical Research: Potential use as a tool compound or precursor for enzyme inhibitors and receptor modulators in biochemical assays.
• Custom Synthesis: Basis for the preparation of labeled analogs (e.g., deuterated, C13) for pharmacokinetic and metabolic studies.

Basic Information

Product Name	tert-Butyl 3-Hydroxy-6,6-Dimethyl-6,7-Dihydro-1H-Pyrazolo[4,3-B]Pyridine-4(5H)-Carboxylate
CAS No.	1251000-23-3
Molecular Formula	C13H21N3O3
Molecular Weight	267.33 g/mol
Synonyms	tert-Butyl 3-hydroxy-6,6-dimethyl-5,6,7,8-tetrahydro-1H-pyrazolo[4,3-b]pyridine-4-carboxylate; 4(5H)-Carboxylic acid, 6,7-dihydro-3-hydroxy-6,6-dimethyl-1H-pyrazolo[4,3-b]pyridine-, 1,1-dimethylethyl ester; 1,1-Dimethylethyl 3-hydroxy-6,6-dimethyl-6,7-dihydro-1H-pyrazolo[4,3-b]pyridine-4(5H)-carboxylate; 6,7-Dihydro-3-hydroxy-6,6-dimethyl-1H-pyrazolo[4,3-b]pyridine-4(5H)-carboxylic acid tert-butyl ester; tert-Butyl 3-hydroxy-6,6-dimethyl-1,4,5,6,7,8-hexahydropyrazolo[4,3-b]pyridine-4-carboxylate
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to stringent quality protocols suitable for pharmaceutical development. Every batch undergoes comprehensive analytical characterization to ensure identity, purity, and consistency. Certificates of Analysis (COA) are provided, detailing results from HPLC, NMR, and mass spectrometry. We support development with material produced under quality management systems aligned with ISO standards and can provide material suitable for use in cGMP-regulated synthesis upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (15-25°C). The compound may be hygroscopic; keep the container tightly sealed in a dry environment to prevent moisture absorption.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (HPLC)	Retention time corresponds to reference standard
Identification (IR)	Spectrum matches reference
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.